Peterson Wealth Services Grows Stake in Stryker Co. (NYSE:SYK)

Peterson Wealth Services grew its holdings in Stryker Co. (NYSE:SYK) by 0.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 12,828 shares of the medical technology company’s stock after buying an additional 68 shares during the quarter. Stryker makes up about 1.4% of Peterson Wealth Services’ investment portfolio, making the stock its 16th largest holding. Peterson Wealth Services’ holdings in Stryker were worth $4,619,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Stonebridge Financial Group LLC purchased a new stake in Stryker in the 4th quarter worth approximately $4,553,000. Mill Creek Capital Advisors LLC lifted its stake in shares of Stryker by 22.3% in the 4th quarter. Mill Creek Capital Advisors LLC now owns 745 shares of the medical technology company’s stock valued at $268,000 after purchasing an additional 136 shares during the period. Sapient Capital LLC lifted its stake in shares of Stryker by 7.0% in the 4th quarter. Sapient Capital LLC now owns 5,190 shares of the medical technology company’s stock valued at $1,873,000 after purchasing an additional 341 shares during the period. Sycomore Asset Management lifted its stake in shares of Stryker by 16.2% in the 4th quarter. Sycomore Asset Management now owns 47,578 shares of the medical technology company’s stock valued at $17,192,000 after purchasing an additional 6,643 shares during the period. Finally, Soltis Investment Advisors LLC lifted its stake in shares of Stryker by 7.4% in the 4th quarter. Soltis Investment Advisors LLC now owns 1,350 shares of the medical technology company’s stock valued at $486,000 after purchasing an additional 93 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Up 0.2 %

Stryker stock opened at $392.15 on Tuesday. The firm has a market cap of $149.50 billion, a price-to-earnings ratio of 50.53, a PEG ratio of 2.98 and a beta of 0.96. The stock has a fifty day simple moving average of $377.23 and a two-hundred day simple moving average of $365.14. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company earned $3.46 earnings per share. Equities analysts predict that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SYK shares. Evercore ISI raised their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group raised their target price on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research note on Thursday, January 30th. Needham & Company LLC restated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. UBS Group raised their target price on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Finally, Truist Financial lifted their price objective on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $420.68.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.